Matthias Budt
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Matthias Budt has a total of 175 co-authors. Here are the top co-authors by number of shared publications:
- Thorsten Wolff
Robert Koch Institute
10 shared publications Christin Mache
Influenza and Other Respiratory Viruses (Unit 17), Robert Koch Institute, Berlin, Germany
4 shared publications- Ralf Dürrwald
Unit 17, Influenza and Other Respiratory Viruses, Department of Infectious Diseases, National Influenza Centre Robert Koch Institute Berlin Germany
4 shared publications - Stefan Kröger
Respiratory Infections (Unit 36), Robert Koch Institute, Berlin, Germany
4 shared publications - Djin-Ye Oh
Unit 17: Influenza and Other Respiratory Viruses, Robert Koch Institute, 13353 Berlin, Germany
3 shared publications - Max von Kleist
Project group 5 “Systems Medicine of Infectious Disease”, Robert Koch Institute, Berlin, Germany
3 shared publications
Latest Publications
- Open Access
- 26 May 2026
- Published by Springer Nature in Communications Medicine
- Vol. 6 (1)
Monitoring viral evolution and epidemiological characteristics of SARS-CoV-2 during 2022–2023 using Integrated Genomic Surveillance
Background: The continued emergence of SARS-CoV-2 variants with increased transmissibility and immunoevasive properties highlights the necessity to complement genomic surveillance with epidemiological data and laboratory-based assessment of viral phenotypes. Effective surveillance tools must be scalable, cost-efficient, and able to detect and characterize emerging variants in timely manner. Methods: We utilized the Integrated Molecular Surveillance for SARS-CoV-2 (IMSSC2) network to conduct nationwide integrated SARS-CoV-2 genomic surveillance in Germany. SARS-CoV-2-positive samples from diagnostic laboratories were routinely subjected to whole genome sequencing. Epidemiological data from COVID-19 cases infected with BA.1, BA.2, BA.5.1, BQ.1.1, XBB.1.5, XBB.1.9.1, and XBB.1.9.2, notified between 1 December 2021 and 30 April 2023, were analyzed. Complementary, representative virus isolates were examined for immunoevasive properties and replication in human respiratory infection models. Results: Lineage assignments of 4595 SARS-CoV-2 genomes indicate ongoing viral evolution with successive replacement of dominant variants from Delta to Omicron lineages BA.1, BA.2, BA.5.1, BQ.1, and XBB recombinants. Age-stratified epidemiological analyses show higher proportions of BA.1 and BA.2 infections in children. Multivariable logistic regression identifies male sex and increasing age as significant predictors of hospitalization. Phenotypic characterization suggests ongoing adaptation of Omicron variants BA.2, BQ.1.1, XBB.1.5, and XBB.1.9.2 to the upper human respiratory tract and enhanced propagation of XBB.1.9.2 in an alveolar infection model. Conclusion: Integrated genomic, epidemiological and virological approaches enable early assessment of emerging SARS-CoV-2 lineages and demonstrate ongoing adaptation across the human respiratory tract. Our findings show that geographically representative, scalable surveillance provides robust insights into viral evolution, supporting sustainable surveillance beyond the acute pandemic phase.
- 26 May 2026
- Published by Springer Nature in Communications Medicine
- Vol. 6 (1)
Open AccessMonitoring viral evolution and epidemiological characteristics of SARS-CoV-2 during 2022–2023 using Integrated Genomic Surveillance
Background: The continued emergence of SARS-CoV-2 variants with increased transmissibility and immunoevasive properties highlights the necessity to complement genomic surveillance with epidemiological data and laboratory-based assessment of viral phenotypes. Effective surveillance tools must be scalable, cost-efficient, and able to detect and characterize emerging variants in timely manner. Methods: We utilized the Integrated Molecular Surveillance for SARS-CoV-2 (IMSSC2) network to conduct nationwide integrated SARS-CoV-2 genomic surveillance in Germany. SARS-CoV-2-positive samples from diagnostic laboratories were routinely subjected to whole genome sequencing. Epidemiological data from COVID-19 cases infected with BA.1, BA.2, BA.5.1, BQ.1.1, XBB.1.5, XBB.1.9.1, and XBB.1.9.2, notified between 1 December 2021 and 30 April 2023, were analyzed. Complementary, representative virus isolates were examined for immunoevasive properties and replication in human respiratory infection models. Results: Lineage assignments of 4595 SARS-CoV-2 genomes indicate ongoing viral evolution with successive replacement of dominant variants from Delta to Omicron lineages BA.1, BA.2, BA.5.1, BQ.1, and XBB recombinants. Age-stratified epidemiological analyses show higher proportions of BA.1 and BA.2 infections in children. Multivariable logistic regression identifies male sex and increasing age as significant predictors of hospitalization. Phenotypic characterization suggests ongoing adaptation of Omicron variants BA.2, BQ.1.1, XBB.1.5, and XBB.1.9.2 to the upper human respiratory tract and enhanced propagation of XBB.1.9.2 in an alveolar infection model. Conclusion: Integrated genomic, epidemiological and virological approaches enable early assessment of emerging SARS-CoV-2 lineages and demonstrate ongoing adaptation across the human respiratory tract. Our findings show that geographically representative, scalable surveillance provides robust insights into viral evolution, supporting sustainable surveillance beyond the acute pandemic phase.
- Open Access
- 11 April 2026
- Published by MDPI AG in Microorganisms
- Vol. 14 (4) , 859
Historical Pandemic and Contemporary Influenza A Viruses Reveal PB2 M631L as a Convergent Adaptation to Human ANP32
Understanding the genetic changes that allow avian influenza A viruses (IAVs) to switch their natural hosts and establish productive infection in humans is important for pandemic risk assessment. Adaptations in the IAV polymerase are required to overcome species-specific restrictions imposed by host ANP32 proteins. Notably, avian virus polymerase is generally only poorly supported by human ANP32 proteins due to species-specific differences. Consequently, efficient polymerase adaptation to the binding interface of human ANP32 requires distinct amino acid changes, such as PB2 E627K. A separate adaptation, PB2 M631L, has recently been reported in mammalian-adapted IAV; however, its functional role across divergent viral lineages and its relationship to host ANP32-dependent adaptation remain incompletely defined. Here, we examine PB2 M631L in the polymerases of a 1918 pandemic strain, a recombinant contemporary H1N1pdm09, and a recent clade 2.3.4.4b H5N1 virus. Using polymerase activity and protein-interaction assays, we show that PB2 M631L enhances polymerase activity and ANP32 binding in human—but not avian—contexts, and that this effect is conserved across multiple viral backgrounds. In H1N1pdm09, PB2 M631L also increased virus replication in mammalian cells. These findings indicate that PB2 M631L contributes to enhanced polymerase compatibility with human ANP32 proteins and are consistent with a role in adaptation across multiple influenza virus lineages. Our results highlight how analysis of historical pandemic strains can inform risk assessment for future emerging viruses.
- 11 April 2026
- Published by MDPI AG in Microorganisms
- Vol. 14 (4) , 859
Open AccessHistorical Pandemic and Contemporary Influenza A Viruses Reveal PB2 M631L as a Convergent Adaptation to Human ANP32
Understanding the genetic changes that allow avian influenza A viruses (IAVs) to switch their natural hosts and establish productive infection in humans is important for pandemic risk assessment. Adaptations in the IAV polymerase are required to overcome species-specific restrictions imposed by host ANP32 proteins. Notably, avian virus polymerase is generally only poorly supported by human ANP32 proteins due to species-specific differences. Consequently, efficient polymerase adaptation to the binding interface of human ANP32 requires distinct amino acid changes, such as PB2 E627K. A separate adaptation, PB2 M631L, has recently been reported in mammalian-adapted IAV; however, its functional role across divergent viral lineages and its relationship to host ANP32-dependent adaptation remain incompletely defined. Here, we examine PB2 M631L in the polymerases of a 1918 pandemic strain, a recombinant contemporary H1N1pdm09, and a recent clade 2.3.4.4b H5N1 virus. Using polymerase activity and protein-interaction assays, we show that PB2 M631L enhances polymerase activity and ANP32 binding in human—but not avian—contexts, and that this effect is conserved across multiple viral backgrounds. In H1N1pdm09, PB2 M631L also increased virus replication in mammalian cells. These findings indicate that PB2 M631L contributes to enhanced polymerase compatibility with human ANP32 proteins and are consistent with a role in adaptation across multiple influenza virus lineages. Our results highlight how analysis of historical pandemic strains can inform risk assessment for future emerging viruses.
- Open Access
- 12 March 2026
- Published by Elsevier in Journal of Infection
- Vol. 92 (5) , 106722
Clade 2.3.4.4b H5N1 influenza A virus exhibits high infectivity in human respiratory tract models
- 12 March 2026
- Published by Elsevier in Journal of Infection
- Vol. 92 (5) , 106722
Open AccessClade 2.3.4.4b H5N1 influenza A virus exhibits high infectivity in human respiratory tract models
- Open Access
- 11 November 2025
- Published by Springer Nature in Communications Medicine
- Vol. 5 (1) , 468
A public health perspective of SARS-CoV-2 evolution and surveillance strategies in Germany from 2020 to 2023
This review summarizes key virological parameters of SARS-CoV-2, the clinical spectrum of COVID-19, antiviral options, resistance, and the evolution of SARS-CoV-2 during the first four years of the pandemic. It draws on evidence that has been continuously updated throughout the pandemic by the interdisciplinary working group ‘SARS-CoV-2 Diagnostics and Evolution’ at Robert Koch Institute (RKI), Germany’s national public health institute. We describe basic SARS-CoV-2 characteristics and highlight notable virus variants from 2020 to mid-2023. During this period, the nationwide collection of SARS-CoV-2 genomes provided a substantial resource for monitoring viral lineage frequencies and mutations. We summarize this dataset to underscore the importance of virological surveillance in the context of public health and pandemic preparedness.
- 11 November 2025
- Published by Springer Nature in Communications Medicine
- Vol. 5 (1) , 468
Open AccessA public health perspective of SARS-CoV-2 evolution and surveillance strategies in Germany from 2020 to 2023
This review summarizes key virological parameters of SARS-CoV-2, the clinical spectrum of COVID-19, antiviral options, resistance, and the evolution of SARS-CoV-2 during the first four years of the pandemic. It draws on evidence that has been continuously updated throughout the pandemic by the interdisciplinary working group ‘SARS-CoV-2 Diagnostics and Evolution’ at Robert Koch Institute (RKI), Germany’s national public health institute. We describe basic SARS-CoV-2 characteristics and highlight notable virus variants from 2020 to mid-2023. During this period, the nationwide collection of SARS-CoV-2 genomes provided a substantial resource for monitoring viral lineage frequencies and mutations. We summarize this dataset to underscore the importance of virological surveillance in the context of public health and pandemic preparedness.
- Open Access
- 6 June 2025
- Published by Springer Nature in Research Square
Integrated Genomic and Virological SARS-CoV-2 Surveillance in Germany 2022/23: Monitoring Viral Evolution and Epidemiological Characteristics
The continued emergence of new SARS-CoV-2 variants with increased transmissibility and immunoevasive properties highlights the necessity to complement genomic pathogen surveillance with epidemiological data and laboratory-based evaluation of virus variants. Throughout this study, we analyzed over 4,500 SARS-CoV-2 genomes gathered from a nationwide laboratory network from December 1st, 2021, to April 30th, 2023. Lineage assignments revealed ongoing dynamic viral evolution in this advanced phase of the COVID-19 pandemic with subsequent replacements of dominant variants from Delta to Omicron lineages BA.1, BA.2, BA.5.1, and BQ.1, to XBB recombinants. Case-based data analysis showed a higher incidence of BA.2 infections in children compared to other lineages within the same age groups. Furthermore, a multivariable logistic regression model identified male sex and increasing age as significant predictors of hospitalization. Evaluation of representative virus isolates in primary cell cultures suggested an ongoing adaptation to the upper human respiratory tract for Omicron BA.2, BQ.1.1, XBB.1.5, and XBB.1.9.2, as well as increased propagation of XBB.1.9.2 in an alveolar infection model. Collectively, this study underscores the public health importance of implementing strategies to assess the risk of emerging SARS-CoV-2 lineages and demonstrates ongoing intrinsic adaptation of SARS-CoV-2 variants to all compartments of the human respiratory tract.
- 6 June 2025
- Published by Springer Nature in Research Square
Open AccessIntegrated Genomic and Virological SARS-CoV-2 Surveillance in Germany 2022/23: Monitoring Viral Evolution and Epidemiological Characteristics
The continued emergence of new SARS-CoV-2 variants with increased transmissibility and immunoevasive properties highlights the necessity to complement genomic pathogen surveillance with epidemiological data and laboratory-based evaluation of virus variants. Throughout this study, we analyzed over 4,500 SARS-CoV-2 genomes gathered from a nationwide laboratory network from December 1st, 2021, to April 30th, 2023. Lineage assignments revealed ongoing dynamic viral evolution in this advanced phase of the COVID-19 pandemic with subsequent replacements of dominant variants from Delta to Omicron lineages BA.1, BA.2, BA.5.1, and BQ.1, to XBB recombinants. Case-based data analysis showed a higher incidence of BA.2 infections in children compared to other lineages within the same age groups. Furthermore, a multivariable logistic regression model identified male sex and increasing age as significant predictors of hospitalization. Evaluation of representative virus isolates in primary cell cultures suggested an ongoing adaptation to the upper human respiratory tract for Omicron BA.2, BQ.1.1, XBB.1.5, and XBB.1.9.2, as well as increased propagation of XBB.1.9.2 in an alveolar infection model. Collectively, this study underscores the public health importance of implementing strategies to assess the risk of emerging SARS-CoV-2 lineages and demonstrates ongoing intrinsic adaptation of SARS-CoV-2 variants to all compartments of the human respiratory tract.
- Top Cited PapersOpen Access
- 29 January 2025
- Published by Springer Nature in Nature
- Vol. 639 (8053) , 196-204
SARS-CoV-2 evolution on a dynamic immune landscape
Since the onset of the pandemic, many SARS-CoV-2 variants have emerged, exhibiting substantial evolution in the virus’ spike protein1, the main target of neutralizing antibodies2. A plausible hypothesis proposes that the virus evolves to evade antibody-mediated neutralization (vaccine- or infection-induced) to maximize its ability to infect an immunologically experienced population1,3. Because viral infection induces neutralizing antibodies, viral evolution may thus navigate on a dynamic immune landscape that is shaped by local infection history. Here we developed a comprehensive mechanistic model, incorporating deep mutational scanning data4,5, antibody pharmacokinetics and regional genomic surveillance data, to predict the variant-specific relative number of susceptible individuals over time. We show that this quantity precisely matched historical variant dynamics, predicted future variant dynamics and explained global differences in variant dynamics. Our work strongly suggests that the ongoing pandemic continues to shape variant-specific population immunity, which determines a variant’s ability to transmit, thus defining variant fitness. The model can be applied to any region by utilizing local genomic surveillance data, allows contextualizing risk assessment of variants and provides information for vaccine design.
- 29 January 2025
- Published by Springer Nature in Nature
- Vol. 639 (8053) , 196-204
Top Cited PapersOpen AccessSARS-CoV-2 evolution on a dynamic immune landscape
Since the onset of the pandemic, many SARS-CoV-2 variants have emerged, exhibiting substantial evolution in the virus’ spike protein1, the main target of neutralizing antibodies2. A plausible hypothesis proposes that the virus evolves to evade antibody-mediated neutralization (vaccine- or infection-induced) to maximize its ability to infect an immunologically experienced population1,3. Because viral infection induces neutralizing antibodies, viral evolution may thus navigate on a dynamic immune landscape that is shaped by local infection history. Here we developed a comprehensive mechanistic model, incorporating deep mutational scanning data4,5, antibody pharmacokinetics and regional genomic surveillance data, to predict the variant-specific relative number of susceptible individuals over time. We show that this quantity precisely matched historical variant dynamics, predicted future variant dynamics and explained global differences in variant dynamics. Our work strongly suggests that the ongoing pandemic continues to shape variant-specific population immunity, which determines a variant’s ability to transmit, thus defining variant fitness. The model can be applied to any region by utilizing local genomic surveillance data, allows contextualizing risk assessment of variants and provides information for vaccine design.
- Open Access
A Global Collaborative Comparison of SARS-CoV-2 Antigenicity Across 15 Laboratories
Setting up a global SARS-CoV-2 surveillance system requires an understanding of how virus isolation and propagation practices, use of animal or human sera, and different neutralisation assay platforms influence assessment of SARS-CoV-2 antigenicity. In this study, with the contribution of 15 independent laboratories across all WHO regions, we carried out a controlled analysis of neutralisation assay platforms using the first WHO International Standard for antibodies to SARS-CoV-2 variants of concern (source: NIBSC). Live virus isolates (source: WHO BioHub or individual labs) or spike plasmids (individual labs) for pseudovirus production were used to perform neutralisation assays using the same serum panels. When comparing fold drops, excellent data consistency was observed across the labs using common reagents, including between pseudovirus and live virus neutralisation assays (RMSD of data from mean fold drop was 0.59). Utilising a Bayesian model, geometric mean titres and assay titre magnitudes (offsets) can describe the data efficiently. Titre magnitudes were seen to vary largely even for labs within the same assay group. We have observed that overall, live Microneutralisation assays tend to have the lowest titres, whereas Pseudovirus Neutralisation have the highest (with a mean difference of 3.2 log2 units between the two). These findings are relevant for laboratory networks, such as the WHO Coronavirus Laboratory Network (CoViNet), that seek to support a global surveillance system for evolution and antigenic characterisation of variants to support monitoring of population immunity and vaccine composition policy.
Open AccessA Global Collaborative Comparison of SARS-CoV-2 Antigenicity Across 15 Laboratories
Setting up a global SARS-CoV-2 surveillance system requires an understanding of how virus isolation and propagation practices, use of animal or human sera, and different neutralisation assay platforms influence assessment of SARS-CoV-2 antigenicity. In this study, with the contribution of 15 independent laboratories across all WHO regions, we carried out a controlled analysis of neutralisation assay platforms using the first WHO International Standard for antibodies to SARS-CoV-2 variants of concern (source: NIBSC). Live virus isolates (source: WHO BioHub or individual labs) or spike plasmids (individual labs) for pseudovirus production were used to perform neutralisation assays using the same serum panels. When comparing fold drops, excellent data consistency was observed across the labs using common reagents, including between pseudovirus and live virus neutralisation assays (RMSD of data from mean fold drop was 0.59). Utilising a Bayesian model, geometric mean titres and assay titre magnitudes (offsets) can describe the data efficiently. Titre magnitudes were seen to vary largely even for labs within the same assay group. We have observed that overall, live Microneutralisation assays tend to have the lowest titres, whereas Pseudovirus Neutralisation have the highest (with a mean difference of 3.2 log2 units between the two). These findings are relevant for laboratory networks, such as the WHO Coronavirus Laboratory Network (CoViNet), that seek to support a global surveillance system for evolution and antigenic characterisation of variants to support monitoring of population immunity and vaccine composition policy.
- Open Access
- 25 April 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-8
Bat-borne H9N2 influenza virus evades MxA restriction and exhibits efficient replication and transmission in ferrets
Influenza A viruses (IAVs) of subtype H9N2 have reached an endemic stage in poultry farms in the Middle East and Asia. As a result, human infections with avian H9N2 viruses have been increasingly reported. In 2017, an H9N2 virus was isolated for the first time from Egyptian fruit bats (Rousettus aegyptiacus). Phylogenetic analyses revealed that bat H9N2 is descended from a common ancestor dating back centuries ago. However, the H9 and N2 sequences appear to be genetically similar to current avian IAVs, suggesting recent reassortment events. These observations raise the question of the zoonotic potential of the mammal-adapted bat H9N2. Here, we investigate the infection and transmission potential of bat H9N2 in vitro and in vivo, the ability to overcome the antiviral activity of the human MxA protein, and the presence of N2-specific cross-reactive antibodies in human sera. We show that bat H9N2 has high replication and transmission potential in ferrets, efficiently infects human lung explant cultures, and is able to evade antiviral inhibition by MxA in transgenic B6 mice. Together with its low antigenic similarity to the N2 of seasonal human strains, bat H9N2 fulfils key criteria for pre-pandemic IAVs.
- 25 April 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-8
Open AccessBat-borne H9N2 influenza virus evades MxA restriction and exhibits efficient replication and transmission in ferrets
Influenza A viruses (IAVs) of subtype H9N2 have reached an endemic stage in poultry farms in the Middle East and Asia. As a result, human infections with avian H9N2 viruses have been increasingly reported. In 2017, an H9N2 virus was isolated for the first time from Egyptian fruit bats (Rousettus aegyptiacus). Phylogenetic analyses revealed that bat H9N2 is descended from a common ancestor dating back centuries ago. However, the H9 and N2 sequences appear to be genetically similar to current avian IAVs, suggesting recent reassortment events. These observations raise the question of the zoonotic potential of the mammal-adapted bat H9N2. Here, we investigate the infection and transmission potential of bat H9N2 in vitro and in vivo, the ability to overcome the antiviral activity of the human MxA protein, and the presence of N2-specific cross-reactive antibodies in human sera. We show that bat H9N2 has high replication and transmission potential in ferrets, efficiently infects human lung explant cultures, and is able to evade antiviral inhibition by MxA in transgenic B6 mice. Together with its low antigenic similarity to the N2 of seasonal human strains, bat H9N2 fulfils key criteria for pre-pandemic IAVs.
- Open Access
- 5 February 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-19
The host RNA polymerase II C-terminal domain is the anchor for replication of the influenza virus genome
The current model is that the influenza virus polymerase (FluPol) binds either to host RNA polymerase II (RNAP II) or to the acidic nuclear phosphoprotein 32 (ANP32), which drives its conformation and activity towards transcription or replication of the viral genome, respectively. Here, we provide evidence that the FluPol-RNAP II binding interface, beyond its well-acknowledged function in cap-snatching during transcription initiation, has also a pivotal role in replication of the viral genome. Using a combination of cell-based and in vitro approaches, we show that the RNAP II C-terminal-domain, jointly with ANP32, enhances FluPol replication activity. We observe successive conformational changes to switch from a transcriptase to a replicase conformation in the presence of the bound RNPAII C-terminal domain and propose a model in which the host RNAP II is the anchor for transcription and replication of the viral genome. Our data open new perspectives on the spatial coupling of viral transcription and replication and the coordinated balance between these two activities.
- 5 February 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-19
Open AccessThe host RNA polymerase II C-terminal domain is the anchor for replication of the influenza virus genome
The current model is that the influenza virus polymerase (FluPol) binds either to host RNA polymerase II (RNAP II) or to the acidic nuclear phosphoprotein 32 (ANP32), which drives its conformation and activity towards transcription or replication of the viral genome, respectively. Here, we provide evidence that the FluPol-RNAP II binding interface, beyond its well-acknowledged function in cap-snatching during transcription initiation, has also a pivotal role in replication of the viral genome. Using a combination of cell-based and in vitro approaches, we show that the RNAP II C-terminal-domain, jointly with ANP32, enhances FluPol replication activity. We observe successive conformational changes to switch from a transcriptase to a replicase conformation in the presence of the bound RNPAII C-terminal domain and propose a model in which the host RNAP II is the anchor for transcription and replication of the viral genome. Our data open new perspectives on the spatial coupling of viral transcription and replication and the coordinated balance between these two activities.
- Open Access
Rise and Fall of SARS-CoV-2 Lineage A.27 in Germany
Here, we report on the increasing frequency of the SARS-CoV-2 lineage A.27 in Germany during the first months of 2021. Genomic surveillance identified 710 A.27 genomes in Germany as of 2 May 2021, with a vast majority identified in laboratories from a single German state (Baden-Wuerttemberg, n = 572; 80.5%). Baden-Wuerttemberg is located near the border with France, from where most A.27 sequences were entered into public databases until May 2021. The first appearance of this lineage based on sequencing in a laboratory in Baden-Wuerttemberg can be dated to early January ’21. From then on, the relative abundance of A.27 increased until the end of February but has since declined—meanwhile, the abundance of B.1.1.7 increased in the region. The A.27 lineage shows a mutational pattern typical of VOIs/VOCs, including an accumulation of amino acid substitutions in the Spike glycoprotein. Among those, L18F, L452R and N501Y are located in the epitope regions of the N-terminal- (NTD) or receptor binding domain (RBD) and have been suggested to result in immune escape and higher transmissibility. In addition, A.27 does not show the D614G mutation typical for all VOIs/VOCs from the B lineage. Overall, A.27 should continue to be monitored nationally and internationally, even though the observed trend in Germany was initially displaced by B.1.1.7 (Alpha), while now B.1.617.2 (Delta) is on the rise.
Open AccessRise and Fall of SARS-CoV-2 Lineage A.27 in Germany
Here, we report on the increasing frequency of the SARS-CoV-2 lineage A.27 in Germany during the first months of 2021. Genomic surveillance identified 710 A.27 genomes in Germany as of 2 May 2021, with a vast majority identified in laboratories from a single German state (Baden-Wuerttemberg, n = 572; 80.5%). Baden-Wuerttemberg is located near the border with France, from where most A.27 sequences were entered into public databases until May 2021. The first appearance of this lineage based on sequencing in a laboratory in Baden-Wuerttemberg can be dated to early January ’21. From then on, the relative abundance of A.27 increased until the end of February but has since declined—meanwhile, the abundance of B.1.1.7 increased in the region. The A.27 lineage shows a mutational pattern typical of VOIs/VOCs, including an accumulation of amino acid substitutions in the Spike glycoprotein. Among those, L18F, L452R and N501Y are located in the epitope regions of the N-terminal- (NTD) or receptor binding domain (RBD) and have been suggested to result in immune escape and higher transmissibility. In addition, A.27 does not show the D614G mutation typical for all VOIs/VOCs from the B lineage. Overall, A.27 should continue to be monitored nationally and internationally, even though the observed trend in Germany was initially displaced by B.1.1.7 (Alpha), while now B.1.617.2 (Delta) is on the rise.